Why the study?
Neuroleptic malignant syndrome is difficult to diagnose and treat when patients lack characteristic symptoms, and it remains unclear whether adjusting doses of previously prescribed neuroleptics can provoke the syndrome.
Answers are grounded in this paper and cite their sources.
This case highlights that seemingly minor alterations in existing antipsychotic medication regimens may potentially trigger neuroleptic malignant syndrome.
Neuroleptic malignant syndrome (NMS) is a rare, potentially lethal syndrome known to be related to the initiation of dopamine antagonist medications or rapid withdrawal of dopaminergic medications. It is a diagnosis of exclusion with a known sequela of symptoms, but not all patients experience these characteristic symptoms making it difficult at times to diagnose and treat. Herein, we present a unique case of NMS with unclear etiology and a unique clinical course. Our case report also raises the question of whether or not adjusting doses of previously prescribed neuroleptic medications can provoke NMS, providing valuable information for providers treating these complex patients.
No takes yet. Share an insight, caveat, or question.
Olson et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: